Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms
Copyright © 2020 Elsevier Inc. All rights reserved..
Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Hematology/oncology clinics of North America - 35(2021), 2 vom: 01. Apr., Seite 409-429 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pemmaraju, Naveen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.10.2 |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 03.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hoc.2020.12.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321997611 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321997611 | ||
| 003 | DE-627 | ||
| 005 | 20231225181109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hoc.2020.12.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM321997611 | ||
| 035 | |a (NLM)33641877 | ||
| 035 | |a (PII)S0889-8588(20)30158-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pemmaraju, Naveen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 03.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a IMiD | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Interferon ICI | |
| 650 | 4 | |a JAK-STAT | |
| 650 | 4 | |a MPN | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a STAT Transcription Factors |2 NLM | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Chen, Natalie C |e verfasserin |4 aut | |
| 700 | 1 | |a Verstovsek, Srdan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology/oncology clinics of North America |d 1991 |g 35(2021), 2 vom: 01. Apr., Seite 409-429 |w (DE-627)NLM013047507 |x 1558-1977 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:2 |g day:01 |g month:04 |g pages:409-429 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hoc.2020.12.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 2 |b 01 |c 04 |h 409-429 | ||